RBC praises Ligand Pharma stock for diversified growth and investment catalysts

On Tuesday, RBC Capital initiated coverage on Ligand Pharmaceuticals (NASDAQ:LGND) stock, awarding the company an Outperform rating and setting a price target of $130.00 per share.

Ligand, recognized for its unique role as a drug royalty aggregator, was praised for its business model that facilitates growth and provides technology and capital to the biopharmaceutical industry.

The company’s earnings per share (EPS) are projected to rise from $2.44 in 2022 to over $10.00 by 2028, indicating a compound annual growth rate (CAGR) of approximately 27% during this period, with a 20% increase expected from 2023. RBC Capital’s assessment suggests that Ligand’s diversified, high-margin growth trajectory is a key factor in its positive outlook.

Ligand’s strategy involves collaborating with partners to develop and commercialize innovative pharmaceuticals. The firm’s financial guidance indicates robust growth potential, which is a driving force behind the Outperform rating.

RBC Capital anticipates that as Ligand continues to meet its growth targets, the market will respond favorably, potentially leading to a re-rating of the company’s shares.

In addition to its growth prospects, Ligand is expected to benefit from investment-related catalysts. These catalysts, which are anticipated to occur regularly, could provide additional upside to the company’s value. RBC Capital’s price target reflects confidence in Ligand’s ability to capitalize on these opportunities and deliver substantial growth over the coming years.

In other recent news, Palvella Therapeutics and Pieris Pharmaceuticals (NASDAQ:) have announced plans to merge, creating a combined entity focused on rare genetic skin diseases.

The all-stock transaction, expected to close in the fourth quarter of 2024, is projected to result in a company with approximately $80.5 million in cash and cash equivalents. The merged entity will continue to operate under the Palvella Therapeutics name.

In parallel, Ligand Pharmaceuticals has finalized the acquisition of APEIRON Biologics for $100 million, potentially supplemented by up to $28 million based on future milestones.

Additionally, Ligand received FDA approval for Ohtuvayre, a novel treatment for chronic obstructive pulmonary disease, developed in partnership with Verona Pharma (NASDAQ:). This approval is set to trigger a $5.8 million milestone payment and an additional $13.8 million upon the drug’s commercial launch in 2024.

Analysts from Craig-Hallum and H.C. Wainwright have maintained a Buy rating on Ligand’s stock, reflecting confidence in the company’s growth potential. Ligand is projected to generate earnings of over $6.00 per share next year, an increase from this year’s $5.01 per share. These recent developments represent strategic growth initiatives for both Palvella and Ligand, highlighting their robust pipelines and potential for future advancements.

InvestingPro Insights

As Ligand Pharmaceuticals (NASDAQ:LGND) garners an optimistic Outperform rating from RBC Capital, real-time data from InvestingPro provides a deeper financial perspective on the company. Ligand’s market capitalization stands at approximately $1.95 billion, reflecting its significant presence in the biopharmaceutical industry. Despite a challenging revenue trajectory in the last twelve months as of Q1 2024, with a decline of 41.92%, Ligand maintains a high gross profit margin of 71.67%, indicating efficient cost management relative to its revenue.

InvestingPro Tips highlight Ligand’s strong liquidity position, as the company holds more cash than debt and has liquid assets that exceed short-term obligations. This financial stability is crucial for investors considering the company’s growth potential. Additionally, the stock’s recent performance has been noteworthy, with a substantial price uptick over the last six months and a return of nearly 60% over the past year, trading near its 52-week high. These metrics underscore Ligand’s robust market performance and may bolster investor confidence as the company strives to achieve the ambitious EPS targets set forth by RBC Capital.

For those seeking a comprehensive analysis of Ligand Pharmaceuticals, InvestingPro offers additional insights. With a total of 12 InvestingPro Tips available, investors can gain a more nuanced understanding of the company’s financial health and market position. To access these insights and more, consider using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking the full potential of InvestingPro’s analytical tools.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.